aMpylation (adenylylation) has been recognized as an important post-translational modification that is used by pathogens to regulate host cellular proteins and their associated signaling pathways. aMpylation has potential functions in various cellular processes, and it is widely conserved across both prokaryotes and eukaryotes. However, despite the identification of many aMpylators, relatively few candidate substrates of aMpylation are known. this is changing with the recent development of a robust and reliable method for identifying new substrates using protein microarrays, which can markedly expand the list of potential substrates. Here we describe procedures for detecting aMpylated and auto-aMpylated proteins in a sensitive, high-throughput and nonradioactive manner. the approach uses high-density protein microarrays fabricated using nucleic acid programmable protein array (nappa) technology, which enables the highly successful display of fresh recombinant human proteins in situ. the modification of target proteins is determined via copper-catalyzed azide-alkyne cycloaddition (cuaac). the assay can be accomplished within 11 h.
IntroDuctIon
In the 1960s, AMPylation (adenylylation) was first found to modulate the activity of Escherichia coli glutamine synthetase through adenylylation and de-adenylylation 1 . However, the functions and molecular mechanism of this modification in the regulation of biological processes were not elucidated until 2009 when Orth and Dixon found that AMPylation can induce cytoskeletal collapse and cytotoxicity in mammalian cells during Vibrio parahaemolyticus and Histophilus somni infections, respectively [2] [3] [4] . Soon after that, Muller and others' studies revealed a reversible AMPylation mechanism mediated by two Legionella pneumophila effectors, DrrA/SidM and SidD, for host vesicle transportation [5] [6] [7] . As in phosphorylation, in which kinases transfer γ-phosphate in ATP, the AMPylation enzyme, or AMPylator, delivers AMP to the tyrosine or threonine residues of their respective substrates. To date, there are two AMPylation domains that have been defined, including a Fic domain (i.e., VopS from V. parahaemolyticus and IbpA from H. somni) and an adenylyltransferase domain (i.e., DrrA from L. pneumophila) 4, 6, 7 . In view of the Fic protein domain's conservation in over 3,000 species including archaea, bacteria, viruses, viroids and eukaryotes ( Fig. 1) 8, 9 , AMPylation could regulate many potential functions in a variety of cellular processes 3, 4, [10] [11] [12] . For example, Yarbrough and Woolery found that a bacterial Fic AMPylator, VopS, modifies host Rho GTPases, blocks their interaction to downstream targets, and alters NF-κB, Erk and JNK signaling 3, 11, 13 . By using the fly as a genetic model, Rahman revealed that Drosophila Fic (dFic) controlled visual neurotransmission, and the flies became blind with the ablation of dFic by mutations 12 . Ham further identified a substrate, BiP, for dFic and demonstrated their participation in the unfolded protein response pathway 13 . However, the role of AMPylation is only beginning to be elucidated because, until recently, there have been no robust methods for identifying substrates of these enzymes. The early methods developed to find AMPylation substrates, including anti-AMPylation antibodies, mass spectrometry and cell-based pull-down assays, revealed only a half-dozen potential targets combined 3, 4, [14] [15] [16] [17] [18] [19] .
To address this need, we developed a high-throughput screening platform using NAPPA, which allows nonradioactive detection of AMPylated and auto-AMPylated proteins with high sensitivity and specificity in an unbiased manner. Traditional protein arrays rely on printing purified proteins. With the NAPPA method, purified plasmid cDNA is printed on an amino-modified microscopic slide along with an anti-tag antibody, BSA and a bis(sulfosuccinimidyl)suberate (BS3) cross-linker. This material is allowed to dry, and it can be stored anhydrously at ambient temperature for months without losing activity. At the time of use, the cDNA is transcribed and translated in situ into the recombinant proteins of interest using a mammalian cell-free expression system, and it is then captured to the array surface through a fusion tag-anti-tag antibody with high affinity and specificity ( Fig. 2) 20, 21 . Several in vitro transcription/translation cell-free expression systems are commercially available, depending on the target protein(s): for example, human HeLa cell lysate and rabbit reticulocyte lysate 10, 22 . NAPPA makes use of our laboratory's large >200,000-plasmid repository (DNASU Plasmid Repository, https://dnasu.org/), which includes 13,000+ plasmids that encode unique human genes, as well as plasmids representing whole genomes for model systems and human pathogens.
Before the AMPylation assay, the array printed with cDNA is incubated with a human HeLa cell-free expression system, which executes the coupled transcription and translations within 2 h. After protein expression and display, the plasmid cDNA is removed with DNase in order to decrease nonspecific binding between the DNA and AMPylation reagents. Array quality control includes assessing overall printing and DNA deposition using a fluorescent DNA stain and the analyses of protein display using an anti-tag antibody. For example, in our GST-tagged protein microarrays, the protein display correlation across arrays is R > 0.90 using a mouse GST-specific antibody and a fluorescently labeled anti-mouse antibody, indicating a high reproducibility in the fabrication of NAPPA arrays (Fig. 3) 10, 23 .
Over the past decade, activity-based protein profiling (ABPP) using bioorthogonal chemical probes has become a powerful technology to screen for target proteins modified by active enzymes. Central to this approach is the ability to link two molecules covalently in highly specific reactions. Among the most successful chemistries is CuAAC, in which one participant is labeled with an alkyne group that reacts with the other participant labeled with an azide group 24 . The reaction is highly efficient, requires the presence of copper to trigger the reaction and has negligible background, even in a complex mixture. The assay using bioorthogonal chemistry is also nonradioactive, robust and sensitive. The specificity and efficiency of this method, which are far superior to typical antibody-mediated interactions, and the smaller steric profiles of the alkyne and azide groups compared with common protein tags, made this the first choice for the development of a high-throughput AMPylation screening platform on NAPPA arrays 10, 25 .
To perform AMPylation screening, the expressed NAPPA arrays are incubated with N6-propargyl-ATP (N 6 pATP), alkynecontaining ATP analog and AMPylator enzyme to execute the transfer of N 6 -modified AMP to its substrates. After washing away the excess ATP analog, the AMPylated proteins on the array can be detected with azide-rhodamine (az-rho) based on CuAAC (Fig. 2) . The slides are then scanned using a microarray scanner, and the signal of substrate AMP labeling via fluorescent rhodamine is quantified using software for microarray data analysis. Finally, potential substrates are selected by comparing the slides probed with active enzyme to slides with either assay buffer alone or treated with inactive mutant enzymes (if available) as a negative control. Figure 2 | Outline of the NAPPA protocol for the detection of AMPylation substrates. NAPPA arrays printed with 13,000+ human plasmid cDNAs are blocked with Tris-based SuperBlock solution to decrease nonspecific interactions (Steps 1-4). The cDNA is then subjected to in vitro transcription and translation (IVTT) to express recombinant tagged proteins using a cell-free expression system. The proteins are captured and displayed in situ by the anti-tag antibody with high specificity and affinity (Steps 5-9). DNA is removed to decrease nonspecific binding using DNase (Steps 10-12).
Applications of the method
GTPγS is added in case the proteins require GTP for their activation, such as GTPases (Steps 13-17). Next, the arrays are incubated with N 6 pATP and AMPylator enzyme to allow the transfer of AMP to the substrates (Steps 18 and 19). The arrays are washed, and the AMPylated proteins on the array are labeled az-rho through CuAAC (Steps [20] [21] [22] . Finally, the slides are scanned using a microarray scanner (Steps [23] [24] [25] [26] [27] [28] [29] and the signal of substrate AMP labeling is quantified using software for microarray data analysis (Steps 30-34; not shown). The AMPylators used for screening can be the enzymes with Fic and adenylyltransferase domains.
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Wash GTPγS identified dozens of novel human substrates that were selectively confirmed both in vitro and in vivo. We found a novel AMPylation inhibition mechanism by phosphorylation on a novel non-GTPase substrate protein, LyGDI, in vitro. In addition, we detected the auto-AMPylation of both the wild-type and mutant (E234G) mammalian AMPylator, HYPE on NAPPA in a previous study 10 and the experiment described here (Fig. 4) , respectively. E234G is an active HYPE mutant in which auto-AMPylation and AMPylation activity is substantially enhanced after removing the inhibitory Glu234 that competes with binding of Arg374 to ATP γ-phosphate 26, 27 . These results demonstrated that this method works to identify substrates of AMPylators with different folding domains from different species, as well as potential new AMPylators with auto-AMPylation activity. More in-depth characterization of AMPylation substrates and mechanisms will facilitate a better understanding of the functional consequences of AMPylation performed by endogenous and exogenous sources 10 . Moreover, the strategy described here could be adapted to other forms of post-translational modifications. In addition, we previously demonstrated the assembly of multiprotein complexes on NAPPA arrays, indicating the potential of our method to identify the modified substrates when complexed 20 .
Comparison of AMPylation screening methods
A variety of methods have been developed to screen for potential AMPylation substrates using mass spectrometry and NAPPA protein microarrays. A detailed comparison of these methods is in Table 1 . The advantages of mass spectrometry-based screening methods are their abilities to analyze natural proteins in biological samples, such as cell lysates and tissue, with high sensitivity and flexibility. However, only a limited number of bacterial and mammalian AMPylator substrates have been identified using mass spectrometry 13, 14, [16] [17] [18] [19] . Possible reasons for this may be due to the temporal and spatial expression or low abundance of target proteins in cells, low affinity and specificity of capture molecules, or loss of proteins during pull-down and sample preparation for mass spectrometry.
The use of protein microarrays appears to eliminate the challenge of studying low-abundance proteins, as the proteins are displayed in an unbiased manner on the array 23, [28] [29] [30] [31] [32] . By combining click chemistry with NAPPA, we identified 27 potential substrates of VopS and 29 potential substrates of IbpAFic2, thus increasing the total number of reported targets for those enzymes about tenfold [14] [15] [16] [17] [18] [19] . Moreover, two new GTPase substrates (Rac2 and Rac3) were selectively validated in HEK293T cells using a V. parahaemolyticus stain containing VopS only 10 . It will be important to perform in vivo confirmation of other substrates that were initially identified in vitro.
Advantages of the method
There are several distinct advantages to using a NAPPA-based approach over other published methods for identifying potential AMPylator substrates. (i) Higher sensitivity: this method has identified many times more candidate substrates compared with all previous methods 10, 14, 15, [17] [18] [19] . (ii) High throughput: thousands of unique proteins can be tested simultaneously-there Array #02 × 100,000
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Figure 3 | Quality control of self-assembled human protein NAPPA microarrays. (a) Expression clones (n = 1,715 human ORFs) encoding the target proteins fused to a C-terminal GST tag were printed along with a polyclonal GST-specific antibody in single spot on the array surface. DNA capture was confirmed by PicoGreen staining (DNA, left), the plasmid DNA was removed using DNase after expression (DNA, middle) and the protein displayed in situ was assessed by a monoclonal GST-specific antibody (GST protein, right; GST color code: red > orange > yellow > green > blue). (b) The correlation coefficient R of GST signal between two NAPPA arrays is 0.92. are currently 13,000 unique human proteins available on the platform with new clones added regularly. (iii) Highly consistent display levels: ~95% of human proteins can be displayed on NAPPA, with very consistent display levels among the proteins. We have found that 93% of proteins have levels within twofold of the mean, which avoids abundance biases and thus tests every protein 21, 23, 33 . (iv) Improved translation using a human cellfree expression system: the use of human ribosomes and chaperones increases the likelihood of complete protein translation and natural protein folding 10, 34 . (v) Fast: the experiment can be performed in only a few days. (vi) Cost-effective: the ability to test so many proteins so quickly substantially lowers the cost of this approach. The NAPPA arrays themselves are cost-effective to produce because preparing and printing DNA is much easier and more reliable than expressing, purifying and printing proteins.
(vii) Nonradioactive: N 6 pATP-based click detection provides an alternative, safe approach compared with radioactive assays.
(viii) Flexibility: this may be the most important advantage of this approach. The use of programmable arrays allows for great flexibility in selecting candidate substrates-as long as cDNAs are available, the corresponding proteins can be included on the arrays. Thus, researchers who wish to test the proteomes of other organisms, or different variations of proteins, such as splice variants or mutants, can be accommodated. With the ability to synthesize genes de novo now, nearly any protein can be included.
Limitations of the method
First, the success of AMPylation substrate screening relies on the availability of an active purified AMPylator enzyme, which can bind and transfer N 6 pATP to probe the arrays. The previous detection of dozens of AMPylation substrates of VopS and lbpAFic, as well as the auto-AMPylation of HYPE on NAPPA, demonstrated the great potential of our method to find substrates of uncharacterized enzymes 10 . The preparation of well-characterized and active AMPylator enzyme is not trivial, and it requires considerable biochemistry efforts. It should be noted that this is a limitation of all in vitro AMPylation screening methods. However, now that a high-throughput method exists for identifying targets, more laboratories will invest in producing purified active 19 Lewallen et al. 16 Pieles et al. 14 Hao et al. 18 Yu et al. 10 AP-MS, affinity purification-mass spectrometry.
enzyme because of the opportunity for greater return. Second, this method relies on having access to NAPPA-based protein microarrays. We have widely published detailed protocols for producing NAPPA arrays, and we have published on recent improvements in the method 21, [35] [36] [37] . In addition, we have published a video tutorial for how to build NAPPA arrays (https://www.youtube. com/watch?v=Ur1fg9jQv04) 36 . Furthermore, researchers who do not have direct access to resources to build, print, screen, scan or analyze their own arrays can make use of our central plasmid repository (https://dnasu.org/) and NAPPA core service and facility (http://nappaproteinarray.org/), which distribute plasmid cDNAs and NAPPA arrays at academic prices 28, 38 . Third, this method can only test targets for which there are available cDNAs. Currently, there are ~13,000 unique genes available for testing; however, efforts are under way to expand this number to obtain one representative clone for every human gene. Fourth, the substrate proteins expressed and displayed on NAPPA may not be folded correctly, may not have appropriate post-translational modifications or may require a cofactor of some kind. For studies on human targets, the use of human lysate, including chaperone proteins to produce the proteins, is favorable compared with most other protein production methods, but it comes with no guarantees. Moreover, the ATP modified with an alkyne group might interfere with the modification of potential substrates. However, we did not observe these issues in our experiments for known AMPylation substrates, which were confirmed with this NAPPA platform 10 . Fifth, as with any in vitro method, candidate substrates may be detected that represent false positives and that may not occur naturally during the course of a true infection. Additional steps will be needed to confirm all detected candidate substrates. Last, NAPPA platform adaptation and optimization will be needed for other post-translational modifications, such as phosphorylation, phosphocholination or UMPylation 39 . Preliminary studies show that phosphorylation can be monitored using anti-phosphorylation antibodies on NAPPA 40 . The development of phosphocholination and UMPylation assays on NAPPA might be executed using anti-phosphocholine antibody 41 and C8-alkyne-dUTP 42 , respectively.
Experimental design Preparation of AMPylators.
Not surprisingly, recombinant bacterial AMPylators used in AMPylation studies have been primarily expressed in bacteria. However, many proteins do not express well in bacteria, giving low or no yield, possibly owing to the size, cytotoxicity and insolubility of target proteins. Bacteria may also not possess the appropriate chaperones and cofactors for folding the recombinant proteins into their native conformations. To circumvent this issue, AMPylator truncations containing only the Fic or adenylyltransferase domain can be constructed, which can be expressed more easily from the bacteria system by reducing the size or hydrophobic part of the protein sequence 3, 4 . Theoretically, the truncations could alter substrate specificity, although these modified forms have yielded a number of verified targets 43 . Cellfree expression is an alternative choice that avoids cytotoxicity, and it has been shown to express many more proteins successfully compared with bacterial expression systems, especially for largesized proteins or membrane proteins 44, 45 . However, it is much more expensive than bacteria, and it would be a second choice if bacteria can produce active protein.
Full-length proteins may also interfere with AMPylation screening, as Engel et al. 26 found an α-helix (α inh ) with a conserved (S/T) XXXE (G/N) motif within Fic AMPylators that prevents ATP γ-phosphate binding and inhibits the enzyme activity. The mutation of this inhibitory motif could markedly enhance the auto-AMPylation and AMPylation of enzymes, e.g., Neisseria meningitidis Fic (NmFic) and Homo sapiens Fic (HYPE) 26 .
Either inactive enzyme or assay buffer can be used as a negative control for high-throughput AMPylation substrate screening. Most Fic AMPylators have a conserved motif (HPFXXGNG) 3, and the adenylyltransferase AMPylators have a conserved motif (G-X11-D-X-D) 6 . Thus, inactive enzyme can sometimes be made by mutating key residues in AMPylators' motifs. For example, the inactive VopS, IbpA and HYPE enzymes were prepared by changing the histidine of Fic motif to alanine 3, 4, 26 . The inactive SidM enzyme was prepared by changing two aspartates of adenylyltransferase motif to alanines 41 . In addition, by comparing the reactions using assay buffer without and with the addition of N6pATP, we may detect the proteins with potential auto-AMPylation.
Preparation of NAPPA protein microarrays. Approximately, 13,000+ sequence-verified human open reading frame (ORF) sequences were transferred into the T7-based mammalian expression vector, pANT7-cGST, which contains a C-terminal GST tag. An advantage of placing the GST tag at the protein C terminus is that the presence of the tag confirms full-length translation of the target protein. We use the antibody specific to the GST tag to assess protein levels because the tag is common to all proteins on the array and because the stoichiometry is only one GST tag per protein. Thus, the signal for binding to GST can be compared from protein to protein as an indirect measure of moles of protein per feature 33. All these plasmids are available in the nonprofit DNASU plasmid repository (https://dnasu.org/). Highly purified plasmid DNA is prepared by our automated DNA factory robot according to the same basic chemistry published previously 35 . NAPPA arrays containing ~2,000 human ORFs per slide were printed by the nonprofit NAPPA Protein Array Core (http://nappaproteinarray.org/) according to previously described methods 21, 35 , and they can be obtained at cost upon request (see above regarding access to arrays in 'Limitations of the method'). Printing and protein display were assessed with PicoGreen and a GST-specific antibody, respectively (Fig. 3) .
Most mammalian cell-free expression systems can be used with NAPPA, including the commercialized rabbit reticulocyte lysate and human HeLa lysate kits. We found that the overall signal intensity and signal-to-noise ratio of protein expression and display and AMPylation on NAPPA were markedly enhanced using a human HeLa lysate-based cell-free expression system instead of reticulocyte lysate-based cell-free expression system 10, 34 . It is possible that expression and folding may be improved by the human ribosomal machinery and chaperones in HeLa cell lysates compared with the rabbit translational machinery 10, 34 .
Removal of plasmid DNA from NAPPA with DNase. After the expression of NAPPA arrays, the plasmid DNA and their corresponding mRNA molecules on the slide's surface might nonspecifically absorb the N 6 pATP, enzyme or fluorescent molecules during incubation, and this might increase the background noise. In our previous experiment, we systematically compared the performance of AMPylation assay using NAPPA with DNase and RNase treatment 10 . The results showed that the background signal decreased after the removal of plasmid DNA from NAPPA using DNase, and the signal-to-noise ratio improved correspondingly. However, we did not observe any additional improvement with the addition of RNase. The results indicated that most of the mRNA molecules were washed away after protein expression, and they did not affect AMPylation screening. This approach can also be applied to different assays on the NAPPA platform such as protein-protein and protein-DNA interactions.
Loading GTPgS to NAPPA arrays. Thus far, most of the confirmed substrates of bacterial AMPylators are GTPases 3,4,10,13,14 . For example, VopS (V. parahaemolyticus) uses AMPylation on activated Rho GTPases, thereby inhibiting downstream signaling pathways (e.g., NF-κB, Erk and JNK) and affecting actin rearrangements. Furthermore, it prevents the degradation of GTPases by E3 ubiquitin ligases 3,4,10,11 . However, SidM and SidD (L. pneumophila) reversibly modify activated Rab1 to regulate host-vesicle trafficking using AMPylation and de-AMPylation, respectively 6, 7 . Thus, we prefer to activate GTPase proteins on NAPPA before AMPylation screening by incubating the array with GTPγS, a nonhydrolyzable GTP analog in which an oxygen of γ-phosphate of GTP is replaced with a sulfur group. The nucleotides that exist on GTPase proteins can be exchanged to GTPγS using 7.5 mM EDTA in Tris-HCl buffer-based solution, and the reaction is then stopped with the addition of 50 mM MgCl 2 (ref.
3). However, this step might not be necessary if there is no evidence of the AMPylator's targets or activity associated with GTPase.
Screening for AMPylation substrates using NAPPA micro arrays and click chemistry. To perform AMPylation screening using NAPPA, the expressed and DNase-treated NAPPA arrays are incubated with N 6 pATP and an AMPylator in AMPylation buffer at 30 °C for 1 h. The optimal assay conditions might differ depending on the specific AMPylator used. After the AMPylation reaction, the modified substrates are detected using az-rho through CuAAC. This method of detection is more sensitive than using antibodies directed at AMPylated peptides 10 . The criteria of target selection are described in detail below (Step 34). To obtain a reliable data set, the screening experiment should be done at least three times on independent days. Only the targets that are reproducibly detected in all experiments should be selected as potential substrates to decrease the number of false positives, which can be a concern particularly in large screenings (e.g., high-throughput arrays).
All standard fluorescence microarray scanners compatible with 75 × 25 mm slides can be used for NAPPA. The procedure is basically the same for different scanners. Here we use the Tecan PowerScanner in our laboratory as an example and show the important parameters for array scanning and obtaining fluorescence images, including laser emission filter, photomultiplier tube (PMT) gain and resolution settings (Steps 23-29) . The wavelengths of the laser for excitation and emission filter need to match with those used for fluorescent rhodamine (586 and 601 nm, respectively). A slight difference in excitation and emission wavelengths between the scanner and fluorescent dye will result in the decrease of quantified signals. Different commercially available fluorescent dyes (i.e., Cy3 and Cy5) conjugated with azide can be used as an alternative. PMT and gain are used for the linear adjustment of signal levels from 0.01 to 1,000%. The PMT and gain should be tested before formal scanning to optimize the dynamic range, such that the background signals are low while ensuring that the strong signals are maximized but not saturated. Increasing resolution will enhance the pixel number for each microarray spot, but it will slow the scanning speed. Normally we use 10 µm resolution for the NAPPA scanning, which takes ~8 min for each slide. The produced fluorescent images are sufficient for the spot examination and subsequent signal quantification.
Validation of selected targets in vitro and in vivo.
Confirmation of selected targets can be performed using an independent rapid bead-based AMPylation assay in vitro 10 . The principle of beadbased AMPylation assay uses GST-tagged substrate proteins that are immobilized on magnetic beads displaying polyclonal anti-GST antibody. The AMPylation reaction is performed by incubating the substrate protein-coated magnetic beads with N 6 pATP and AMPylator. The beads are then washed with PBS/Tween 20 (PBST) and the azide-fluorescein is added so that the substrates that are AMPylated with alkyne will be labeled through CuAAC. Labeled substrate proteins are then released from the beads under heating (95 °C, 5 min) in 1× SDS loading buffer and then loaded on an SDS-PAGE gel, on which the AMPylated substrates are detected through in-gel fluorescence. Comparisons with total substrate protein are accomplished by using the same gel for a western blot with monoclonal GST-specific antibody. The assay can be easily adapted to be of high throughput using a 96-well microplate and a magnet 10 .
Promising substrates eventually require validation in vivo. This is often accomplished in cell-based assays; however, a detailed description of how to validate substrates in vivo is beyond the scope of this article. Such assays require careful optimization, and they must be individualized on the basis of the specific candidates tested. In previous experiments, we have had success with the stable expression of both AMPylator and substrate in cells followed by pull-down and confirmation by either antibodies or mass spectrometry 10 . It should be noted that there are technical reasons that a bona fide substrate may fail to validate in vivo, such as competing post-translational modifications or specific cellular growth requirements.
Bioinformatics is very helpful for prioritizing candidates on the basis of the annotation of their protein classes, functions and subcellular locations, as well as for searching for motifs that are conserved in previously validated substrate candidates. This approach can provide information about network interactions and biological processes 10, 46 . In previous work, we identified a YxPVTF motif (where 'x' = any amino acid) in six GTPases and one non-GTPase protein. We ectopically expressed candidate substrates in HEK293T cells, which were then challenged with a V. parahaemolyticus strain expressing VopS. Target AMPylation was identified by immunoprecipitation using an anti-AMPylation antibody followed by mass spectrometry 10 . Among the five targets tested (Rac2, Rac3, LyGDI, LC3 and LENG1), we confirmed AMP modification by VopS in vivo for Rac2 and Rac3, which contained the YxPVTF motif.
• EQUIPMENT SETUP Programmable chilling/heating incubator setup Set up a program with a temperature of 30 °C for 1.5 h and 15 °C for 0.5 h, which is used for the protein expression on NAPPA arrays. VWR rocking platform setup Set up the rocking platform to the setting of '2' , which is ~50-70 tilts per minute, and use it for washing NAPPA slides after incubation.
Centrifuge setup To remove excess liquid from the slides, set the centrifuge to 1,000g for 2 min at 4 °C. Tecan PowerScanner setup Turn on the scanner and computer to allow connection. Open the microarray scanning software and choose the green laser with the emission filter of 575 ± 30 nm in order to scan NAPPA arrays probed with fluorescent rhodamine. proceDure blocking and in vitro transcription and translation of nappa arrays • tIMInG ~3.5 h 1| Obtain or prepare the NAPPA arrays 21, [35] [36] [37] . Here we use three slides from one array (n = 1,715 human genes per slide) as an example to show the processing of AMPylation assay using NAPPA and click chemistry (Fig. 5a ).
2|
Transfer three slides into a four-well plate, add 3 ml of SuperBlock solution to each well and incubate them at room temperature for 1 h on a rocking platform with the setting of '2' (see Equipment Setup).
3| Wash the slides briefly with H 2 O.
4|
Remove the liquid on the slide surface by centrifugation at 1,000g for 2 min at 4 °C.
5|
Carefully align the HybridWell hybridization chamber to the slides surface and seal the chamber to the slides by rubbing around the seal using a plastic stick (Fig. 5b) .  crItIcal step Avoid touching the HybridWell hybridization chamber to the microarray spots on the glass slides.
6| Inject 140 µl of human cell-free expression system (see Reagent Setup) into the chamber through the hole at the right side of each slide, and seal the holes using a circle sticker (Fig. 5c,d ).  crItIcal step Remove the air bubbles that are generated during the injection by gently tapping the HybridWell while holding the slide at an angle. The presence of bubbles may affect the expression and display of some proteins on NAPPA.  pause poInt Any remaining human cell-free expression system solution can be stored at −80 °C for <1 month. However, the solution should be used within three freeze/thaw cycles to avoid a substantial loss in activity.
7|
Start the in vitro transcription and translation of NAPPA arrays by incubating the slides for 1.5 h at 30 °C, followed by incubating them for 0.5 h at 15 °C in the programmable incubator.
8|
Remove the slide chamber and briefly wash the slides with PBST.
9|
Tap each slide on its edge on a paper towel to remove excess buffer, and immediately go to the next step.
removing the plasmid Dna from nappa arrays • tIMInG ~2 h 10| Transfer 500 µl of 1× DNase to the microarray surface and cover the microscopic slide with a full-length coverslip, and then incubate for 20 min at room temperature.  crItIcal step Avoid the generation of air bubbles during operation.
11|
Remove the digested DNA fragments and DNase by washing the slides three times with PBST, 5 min for each washing.
12|
Transfer the slides into a four-well plate, add 3 ml of 1% (wt/vol) BSA solution to each well and incubate at room temperature for 1 h on a rocking platform with the setting of '2' (see Equipment Setup).
loading Gtpgs to nappa arrays • tIMInG ~1 h 13| Discard the BSA solution and briefly rinse the slides using PBST.
14| Add 2.5 ml of 50 µM GTPγS to each well and incubate the slides for 15 min at 30 °C in the programmable incubator. a b c d
Step 1 Step 5 Step 6 Step 6 16| Wash the slides with GTP washing buffer two times, 5 min for each washing.
17|
Centrifuge the slides (placed on its side in a metal rack such that the protein spots are not in contact with any surface) at 1,000g for 2 min at 4 °C.
nappa aMpylation assay • tIMInG ~3 h 18| Apply a HybridWell hybridization chamber to the slide's surface, and incubate the array with 160 µl of AMPylation solution containing 40 µg/ml VopS and 250 µM N 6 pATP for 1 h at 30 °C. In parallel, we incubate the other two slides with the assay buffer, with and without N 6 pATP, which are used as controls to detect the proteins with AMPylation and auto-AMPylation, respectively (see Experimental design and ANTICIPATED RESULTS).  crItIcal step The concentration of different AMPylators might differ, depending on the enzymes' AMPylation activity. A concentration range of 40-200 µg/ml is recommended.
19|
After the AMPylation reaction, wash the three slides three times with PBST, and then remove the liquid from the slides' surfaces by centrifuging the slides at 1,000g for 2 min at 4 °C.
20|
Apply a HybridWell hybridization chamber, add 165 µl of az-rho solution (see Reagent Setup); incubate for 1 h at room temperature.  crItIcal step Thaw the reagents for 30 min at room temperature before preparing the az-rho solution.
21|
Remove the chamber and wash the slides three times with PBST on the rocking platform with setting of '2', with 5 min for each wash (see Equipment Setup).  crItIcal step The signal-to-noise ratio may be improved by increasing the washing time to overnight at 4 °C.
22|
Remove the liquid from the slides' surfaces by centrifuging the slides at 1,000g for 2 min at 4 °C.
scanning nappa arrays • tIMInG ~1 h for six slides with one setting 23| Load the NAPPA slides into the microarray scanner.
24|
Choose the green laser with a 575/30-nm emission filter for the scanning of fluorescent dyes such as rhodamine, Cy3, DyLight 549, Alexa Fluor 555 and so on.  crItIcal step The user should choose the red laser with a 676/37-nm filter if Cy5, DyLight 649 and Alexa Fluor 647 dyes are used for detection.
25|
Remove the 'autogain' setting, which is the default setting on the scanner.  crItIcal step With 'autogain', an automatic gain will be assigned for each individual slide, and the scanning parameters may change from slide to slide. Herein the 'autogain' is not recommended.
26|
For AMPylation detection with az-rho, we normally choose the PMT from 200 to 400% and a gain of 100% at the resolution of 10 µm. The user can choose to set up multiple settings for each individual slide.  crItIcal step The scanning setting might be different for different fluorescent dyes. Optimize the PMT and gain within a range of 0.01-1,000%, and then choose the optimal setting with clear, nonsaturated fluorescence signals and low background for the image examination and signal quantification.
27|
Define the name of each image and the location where the image needs to be saved.
28| Start the scanning. It takes 10 min to prewarm the laser before array scanning.
29|
The images will be saved in 16-bit TIFF format.
Data quantification and candidate selection • tIMInG ~12 h 30| Extract the average fluorescence signal intensity from microarray spots in a TIFF image and produce a data file (.csv) using the Array-Pro analyzer microarray software.  crItIcal step Most commercial microarray analyzing software can be used for this work, such as ScanArray Express (PerkinElmer) and GenePix (Molecular Devices). There also are several free software applications available, such as P-SCAN and ProteinScan, which can be downloaded from sources listed in ref. 47 .
31|
Open the data file (.csv) using Microsoft Excel 2013 software. Older Excel versions can also be used for this purpose. 32| Normalize the raw signal intensity using the equation below:
where X i,j and, Y i,j are the raw signal intensity and normalized value of each individual spot, respectively. Bkg is the signal value at the first quartile of microarray spots printed with buffer only as negative control, which is assumed to be the background noise induced by the nonspecific binding of ATP analog, the AMPylation enzyme and fluorescent molecules, and M is the median fluorescence intensity of all protein spots.  crItIcal step The aim of data normalization is to decrease the background variation between individual arrays. The equation was generated on the basis of the hypothesis that only a minority of targets exist on high-density NAPPA protein arrays for unbiased screenings, so the median of all protein spots can be used as a measure of background 10, 28, 48 .
33| Examine the array images and remove any obvious false-positive values (i.e., caused by the spot shape, dust, nonspecific binding and so on) according to their position in the image and the data file.
34| Select the candidate targets using the following criteria: first, select proteins with a normalized value of 20% above the median as positives; second, if a parallel screen was performed using an inactive control enzyme as a negative control, calculate the ratio of substrate signal with AMPylator to its buffer or inactive mutant control, and then select the potential substrates with a ratio higher than 1.2; and third, repeat each AMPylation screening experiment three times on independent days. Positive targets in all experiments, as explained in the first two criteria, should be considered substrate candidates.
? troublesHootInG Troubleshooting advice can be found in table 2. Repeat the experiment and ensure that the hybridization chamber is covered on the slide surface with microarray spots Low expression of human proteins on NAPPA arrays (Step 6)
Check the human cell-free expression system for the protein production in vitro, as it may lose its activity during shipment and storage
Check the protein expression on NAPPA or western blot using monoclonal mouse GST-specific antibody 35 The AMPylator may have no AMPylation enzyme activity (Step 18) Check the other post-translational modifications that are mediated by the proteins with Fic domains 39, 49, 50 N 6 pATP may have no activity (Step 18) Check the activity of N 6 pATP using in-gel fluorescence with VopS and Rho GTPase substrates 10, 19 • tIMInG Steps 1-9, blocking and in vitro transcription and translation of NAPPA arrays: ~3. 
antIcIpateD results
The detection of proteins with auto-AMPylation and AMPylation on NAPPA is shown in Figure 4 . In this example, we used a NAPPA array containing 1,715 human full-length proteins and then performed the auto-AMPylation and AMPylation assays as described above (Steps [18] [19] [20] . The first array was incubated with AMPylation buffer to serve as the negative control. The second array was incubated with N 6 pATP in order for us to observe the proteins with auto-AMPylation. The third array was incubated with N 6 pATP and VopS in order for us to detect the AMPylation of VopS substrates. By comparing the second array with the first negative control array, we found that HYPE E234G proteins had a strong fluorescence signal, indicating that HYPE proteins were auto-AMPylated (Fig. 4a) . Moreover, with the addition of VopS, we can see that several additional proteins fluoresced when compared with the second array, indicating that these proteins were specifically modified with AMP by the VopS enzyme. We normalized the fluorescent signal intensity of all human proteins on NAPPA arrays and drew a plot graph (Fig. 4b) . The results indicate that HYPE E234G and several Rho GTPase proteins (e.g., Rac1, Rac2 and RhoA) had substantial normalized values above the control array. These results confirm the ability of our NAPPA to detect proteins with auto-AMPylation and AMPylation. autHor contrIbutIons X.Y. designed and performed the experiments, and wrote the manuscript; J.L. designed the study and wrote the manuscript.
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